ImmunethepEU (govt): grant, 202210 EIC Accelerator grant 2.5m to advance Paragon Novel Vaccine - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal
Summary
This funding aims at advancing the Paragon Novel Vaccine (PNV) to first-in-human clinical trials to assess safety, immunogenicity, and early efficacy. This report recommends continuing the development and use of vaccines for some of WHO\x92s bacterial priority pathogens list as tools to fight the Antimicrobial Resistance (AMR) threat worldwide. Immunethep has a strong IP portfolio of granted patents covering the discovered mechanism and potential applications, and has in its pipeline two main products addressing 5 different bacteria with alternative strategies: > PNV, a preventive vaccine, ready for first-in-human clinical trials > UNImAb, a therapeutic approach using antibodies that is an alternative to antibiotics, is in the development phase with important milestones already achieved. It has a budget of \x8010.1 billion to support game-changing innovations throughout the lifecycle from early-stage research to proof of concept, technology transfer, and the financing and scaleup of startups and SMEs. In addition to financial support, all projects benefit from a range of Business Acceleration Services that provide access to leading experts, corporates, investors, and ecosystem actors.
Classifications
AskAI Classifications
LabelsLinked Companies
